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N-HYDROXYLATION of 4-acetamidostilbene (AAS) in the rat has been demon-
strated and this has been postulated as a carcinogen activation process since
N-hydroxy-AAS is a more potent carcinogen than the parent amide with a wider
spectrum of tissue reactivity (Andersen et al., 1964; Baldwin, Smith and Surtees,
1963; Baldwin and Smith, 1965; Baldwin et al., 1968). In contrast, two other
hydroxylated metabolites 3-hydroxy-AAS and 4'-hydroxy-AAS are almost
completely inactive (Andersen et al., 1964; Baldwin et al., 1968).
Whilst, however, the liver is involved inthe metabolic formation ofN-hydroxy-
lated compounds and both AAS and N-hydroxy-AAS produce marked liver
damage, the carcinogenic response to these compounds in this tissue is low,
tumours generally arisingin sebaceous glands associated withthe external auditory
meatus (Baldwin et al., 1968). If the mechanism of action of 4-aminostilbene
compoundsisenvisagedasinvolvingdirecttissueinteractionsina manner analogous
to that proposed with other classes of chemical carcinogens (Miller and Miller,
1966, 1967) the reactive metabolites must present in these ear duct glands. This
may result from direct metabolism of carcinogen in the glands or, more likely,
follow liberation of a metabolite formed in the liver and transported as a stable
conjugate. In order to examine the latter possibility, the overall metabolism
of AAS and the N-hydroxy-AAS has been studied in greater detail, particularly
with respect to the formation of conjugated metabolites.
These studies have been carried out with 14C-labelled compounds so that a
quantitative assessment oftheamountsofindividualmetaboliteshasbeenobtained.
Furthermore, the use of 14C-labelled compounds has permitted the identification
of metabolites not detectable by the fluorimetric and colorimetic methods used
in earlier studies (Andersen et al., 1964; Baldwin and Smith, 1965).
MATERIALS AND METHODS
Animals
Adult male rats of an inbred Wistar strain (body weight 160 to 200 g.) were
used. These were kept in pairs in all-glass metabolism cages permitting the
separate collection of urine and faeces whilst providing free access to food (cubed
diet, MRC 41B) and water.
Spectra
Absorption spectra were measured on a Unicam S.P. 500 spectrophotometer
and fluorescence spectra on an Aminco Bowman spectrofluorimeter.4-ACETAMIDOSTILBENE AND ITS N-HYDROXY DERIVATIVE
Measurement of radioactivity
Radioactivity was estimated in a Panax scintillation counter type SC-LP
(Panax Equipment Ltd., Redhill, Surrey) at 40 C. The counting efficiency was
determined by internal standardization and all counts were corrected to 100%
efficiency.
Organic samples (0-1 ml.) were estimated in NE 213 liquid scintillator (4.0 ml.;
Nuclear Enterprises Ltd., Edinburgh). Tissue, urine and faeces samples were
digested in NKOH and aliquots (0.1 ml.) assayed for radioactivity as described by
Brown and Badman (1961).
Thin layer chromatography (TLC)
Thin layer chromatograms, prepared from silica gel, were developed with
either (a) benzene: ethanol (9: 1 v/v) or (b) benzene: acetone (3: 1 v/v). The
chromatographic properties of 4-aminostilbene compounds in these solvent
systems have been described previously (Baldwin and Smith 1965). Metabolites
were detected by their blue fluorescence under ultra-violet light or by spray
reactions. Radioactive metabolites were located either by scanning in a Packard
scanner, Model 7201 (Packard Instrument Co., Inc., Ill.,U.S.A.) orbythedarkening
of X-ray film (Ilford Industrial G., Ilford Ltd., England) exposed to the plates.
For quantitative estimation, zones of silica gel containing metabolites were
removed from the thin layer plates, packed into microcolumns and eluted with
ethanol for radioactive assay.
Preparation ofcompounds
Only the trans isomers of 4-aminostilbene and its derivaties were studied.
4-acetamidostilbene (AAS) m.p. 2340 C. 4'-hydroxy-AAS, m.p. 2380 C. and
N-hydroxy-AAS, m.p. 2000 C. were prepared as previously described (Baldwin
and Smith, 1965). 4'-Hydroxy-4-aminostilbene (4'-hydroxy-AS) m.p. 2730 C.
(Masserani 1957) and 3-hydroxy-AAS, m.p. 211-213° C. (Andersen et al., 1964)
were prepared by the published methods.
4-Acetamidostilbene-fi-14C
4-Nitrostilbene-fi-14C was prepared by the condensation ofp-nitrophenylacetic
acid (100 mg.) withbenzaldehyde(carbonyl-14C)(RadiochemicalCentre,Amersham,
Bucks., England; 0-5 mCi, 53 mg.) in the presence of piperidine (0.15 ml.) at
1400 C. for 2 hours. The mixture was dissolved in ethanol and percolated
through a silicagel column (Mallinckrodt, NewYork, U.S.A., 100 mesh) to separate
the blue fluorescent 4-nitrostilbene. The ethanol solution reduced to small
volume (5 ml.), was warmed to 65° C., treated with hydrazine hydrate (0.2 ml.)
and small portions of freshly prepared Raney nickel added over a one hour
period with stirring. The hot solution was immediately centrifuged (600 g for
5 minutes) and the supernatant treated with a 10 moles excess of acetic anhydride
(0-25 ml.) and refluxed for one hour. The resulting solution was poured into
cold water and the precipitated compound collected by filtration, redissolved in
ethanol and chromatographed on asilica gel column (yield 59 mg.). The compound
migrated with authentic 4-acetamidostilbene on TLCs and had the identical
absorption (maximum at 323 m,t in ethanol; E. 3-5 x 104) and fluorescence
(maximum at 390 m,u) spectra. A trace impurity was detected by radioauto-
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graphy of TLCs (Rf 0 90 in solvent b) accounting for 0.6% of the total radio-
activity. The specific activity of the product was 0-97 mCi/m-mole.
N-hydroxy-4-acetamidostilbene-/3-14C
4-Nitrostilbene-,8-14C, prepared as before from benzaldehyde (carbonyl-14C)
(100 mg., 1 mCi), was dissolved in ether (5 ml.) and treated with aluminium
amalgam (60 mg.) as previously described (Baldwin and Smith, 1965). The
mixture was filtered, the precipitate washed once with ether (5ml.) and the
combined ether solutions treated with acetic anhydride (0.4 ml.) for 16 hours at
40 C. The reaction mixture was then reduced under pressure to small volume
(5 ml.), diluted with an equal volume ofethanol: acetone (1: 1 v/v) and extracted
with 2N NaOH (5 x 10 ml.). The alkaline extract was neutralized with conc.
HC1 and extracted with ether: ethanol: acetone (3: 1: 1 by volume) mixture
(3 x 5 ml.). The organic extract was washed several times with water, dried
over magnesium sulphate and organic solvent removed under reduced pressure.
The residue was recrystallized four times from toluene and the product (yield
13 mg.) in ethanol solution stored in the dark. The radioactive compound
(specific activity 0-74 mCi/m-mole) migrated with authentic N-hydroxy-4-
acetamidostilbene on TLCs and gave the characteristic colour reaction with ferric
chloride-potassium ferricyanide (Baldwin and Smith, 1965). A trace amount
of 4-acetamidostilbene (1.0%) was detected by radioautography of TLCs.
Excretion studies
Rats were injected i.p. with AAS-14C (0.67 mg.; 6 x 106 CPM) or N-hydroxy-
AAS-14C (0*89 mg.; 5-6 x 106 CPM) as suspensions in saline containing 0.5% w/v
carboxymethyl-cellulose (2.0 ml.), and urine and faeces samples were collected
daily for 20 days. Urine samples were centrifuged (600 g for 10 minutes) to
remove any solid contaminants and, unless used immediately, frozen and stored
at -20° C. Faeces samples were either Soxhlet extracted with hot dimethyl-
formamide, which effectively removed all faecal radioactive metabolites, or dried
in vacuo.
Excretion patterns were determined in normal rats and also in rats pre-
treated with either AAS (total dose 163 mg./kg. body weight) or N-hydroxy-AAS
(total dose 39 mg./kg. body weight) administered i.p. thrice weekly for 4 weeks.
In pre-treated rats, 14C-labelled compounds were administered 7 days after the
last injection.
Fractionation of urinary metabolites
Enzymic hydrolysis.-Pooled urine, collected over 48 hours from groups of
rats receiving either AAS-14C (1 mg. : 106 CPM) or N-hydroxy-AAS-14C (0.9 mg.;
5-6 x 106 CPM) was adjusted to pH 6bythe addition of0-3M sodium acetatebuffer
pH 6andextracted 5timeswithanequalvolumeofethertoseparatefreecompounds.
The residual urine was then incubated at 370 C. for 18 hours with,/-glucuronidase
(25 mg.; Type 1 Sigma Chemical Co., St. Louis, Miss., U.S.A.) and again extracted
5 times with ether. The remaining aqueous fraction was then incubated for
18 hours at 370 C. with sulphatase (L. Light, Colnbrook, England) and the
hydrolysate ether extracted as before. Taka diastase (Parke Davis, Hounslow,
England) was used in some studies, but was found to be less effective inhydrolysing
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sulphuric acid conjugates. The aqueous urine residue was finally adjusted to pH 1
with conc HCl and refluxed for 30 minutes. The hydrolysate was then adjusted
to pH 6 with solid sodium bicarbonate and ether extracted. Each of the for-
going ether fractions was extracted with 0-5N NaOH to separate hydroxylated
compounds. After neutralization with conc HCI, metabolites were re-extracted
into ether.
Chromatographic separation.-Chromatographic separation of urinary meta-
bolites on alumina (P. Spence, Widnes, England) was carried out as described by
Weisburger et al. (1961).
Faecal metabolites
Dried faeces samples (2.5 g.) were sucessively extracted in a Soxhlet apparatus
with 100 ml. volumesofether, methanol: chloroform (1: 1 v/v), ethanol and water.
Extracted radioactivity was expressed as a percentage of that extracted with
dimethylformamide which effectively removed all the radioactive metabolites.
Conjugated metabolites in aqueous extracts were liberated by enzymic hydrolysis
as described for urine.
RESULTS
Excretion studies
Following i.p. administration of 14C-AAS (0.67 mg.; 6 x 106 CPM) to rats,
radioactivity was rapidly excreted, 81% of the dose being eliminated by 3 days
(Fig. 1). Metabolites were excreted prefer-entially in the urine (total recovery 55.2% of administered radioactivity), the major portion being eliminated within
24 hours. Faecal excretion did not reach a maximum until after 48 hours and a
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total of 39.3% of the administered radioactivity was excreted by this route.
Only minimal amounts of radioactivity were detected in either urine or faeces
after 20 days and the total recovery of radioactive metabolites at this time
(94.5%) indicates that little of the administered compound is retained for long
periods. The rate of excretion of radioactivity following i.p. administration of
N-hydroxy-AAS-14C (0.89mg.; 5-6 x 106 CPM) did not differ markedly from
that observed with the parent amide, 72% of the dose being eliminated within 3
days (Fig. 1). There was, however, a greater tendency towards faecal excretion,
50% ofthe administered radioactivity being eliminated by this route.
There was no marked difference in the rate of excretion of AAS-14C following
i.p. injection in normal rats compared with those in animals pretreated with the
unlabelled amide or N-hydroxy-AAS. There was, however, a shift towards faecal
rather than urinary excretion, this being more pronounced in rats treated with
N-hydroxy-AAS (Table I).
TABLE I.-Excretion Patterns Following Intraperitoneal Injection of
4-Acetamidostilbene-,/-14C in Carcinogen-treated Rats
Pre-treatment
Percentage recovery of
Total dose radioactivity
mg./kg. A
Compound body weight Urine Faeces Total
None - . 58 2 40 7 98*9
4-Acetamidostilbene 163 . 37.1 51.3 88.4
N-Hydroxy-4-acetamidostilbene 39 . 45.1 59 6 104.7
Each value represents the mean ofthe total radioactivity excreted in two rats 20 days after i.p.
administration of 14C-AAS (0.67 mg.; 6 x 106 CPM).
Metabolism of 4-acetamidostilbene
Urinary metabolites.-Fractionation ofurinary metabolites either by sequential
hydrolysis with bacterial ,-glucuronidase and sulphatase and ether extraction,
or by alumina column chromatography (Weisburger et al., 1961), revealed that
metabolites of AAS-14C were excreted preferentially as sulphuric acid conjugates
together with smaller amounts present as free compounds and glucosiduronic
acid conjugates (Table II). The quantities of various metabolites in fractions
isolated by enzymic hydrolysis ofurine are shown in Table III. In each fraction,
hydroxylated compounds were the major metabolites identified and only small
amounts of unmetabolized amide and the deacetylated 4-aminostilbene (AS)
TABLE II.-Classification of Urinary Metabolites of 4-Acetamidostilbene-14C
Percentage of urinary radioactivity
Sulphuric acid conjugates
Free Ethereal Acid hydrolysed Total
Method of analysis compounds Glucosiduronates sulphates fractions recovery
19-4 14-2 27*3 24*1 85-0
Sequential hydrolysis . 17-2 18-2 26*7 25*4 87 5
Alumina column 28-6 12-7 47*6 88-9
chromatography . . 28.6 9.9 50*7 89.4
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TABLE III.-Urinary Metabolites of 4-Acetamidostilbene
Percentage of urinary radioactivity
Compound Free compounds Glucosiduronates Sulphates
Hydroxylated
metabolites
3-Hydroxy-AAS 22 0 8 0 6
4'-Hydroxy-AAS . 2 7 1 7 3 6
4'-Hydroxy-AS . . 1.0 14 9*3
N-Hydroxy-AAS . 2 5 08
Ml (Rf 036-0.40) . 04 0*4
M2 (RfO* 13-0* 16) . - - 0 3
M3 (Rf 0-04-008) . 5*9 2*7 1.7
Origin . . . O7 16 2*4
Non-hydroxylated
metabolites
AAS . . . . 08 0.1 1*8
AS . . . . 0-2 - 0.1
M4 (Rf 007-0*09) . 1*0
Origin . . . 01 002 0*6
were detected. 4'-Hydroxy-AAS and 4'-hydroxy-AS constituted the major
metabolites conjugated with sulphuric acid, accounting for 12.9% of the total
urinary radioactivity. N-Hydroxy-AAS (0.8%) and 3-hydroxy-AAS (0.6%)
were also detected together with two unidentified metabolites (Rf 0 07 and 0*13 in
solvent b; 2.0%) and material which could not be separated by TLC (2.4%).
Unchanged AAS and the deacetylated compound were also detected (1.9%)
togetherwithanothernon-hydroxylatedmetabolite (Rf 0-08 in solvent b) account-
ing for 1-0% of the urinary radioactivity.
N-Hydroxy-AAS (2.5%) and an unidentified metabolite M3 (Rf 0-06 in
solvent b; 2-7%) were the major metabolites conjugated with glucosiduronic acid.
4'-Hydroxy-AAS and the deacetylated compound together accounted for 3.1%
of the urinary activity in this fraction. A small amount of 3-hydroxy-AAS
(0.8%) was detected together with another unidentified metabolite M1 (Rf 0 37 in
solvent b; 0.4%) and material which could not be separated (1.6%).
An unidentified compound M3 (Rf 0-06 in solvent b) was the major metabolite
detected in an unconjugated form, accounting for 5.9% of the total urinary
radioactivity. 4'-Hydroxy-AAS and 3-hydroxy-AAS (4.9%) and 4'-hydroxy-AS
(1.0%) were present together with N-hydroxy-AAS (1.0%). Unchanged AAS
and the deacetylated compound were detected, but these were only present in
small amounts.
Although appreciable amounts of radioactivity were recovered by ether
extraction of acid hydrolysed urine residues after enzymic treatment (Table II)
none of this material could be separated by TLC, suggesting that the hydrolytic
conditions had resulted in degradation of metabolites. Furthermore, water
soluble metabolites accounting for between 10 and 15% of the total urinary
radioactivity could not be extracted from urine residues after enzymic and acid
hydrolysis and were thus not identifiable.
The metabolite M3 which was detected in all fractions and accounted for 10-3%
of the total urinary radioactivity could not be identified by comparison of its
chromatographic properties on TLCs with any 4-aminostilbene compound. It
gave a blue colour when treated on TLCs with aqueous ferric chloride-potassium
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ferricyanide indicating phenolic properties and it also reacted with acidic
p-dimethylaminobenzaldehyde reagent, although the purple blue coloration
differed from the usual yellow-orange reaction with 4-aminostilbene compounds.
Since stilbene is metabolized to benzoic acid (Stroud, 1940) the possibility
that metabolite M3 was a product of fission of the ethylenic double bond was
examined. Metabolite M3 was clearly distinguishable on TLC in solvent b
from benzoic acid (Rf 0.40), p-hydroxybenzoic acid (Rf 0.28), and p-hydroxy-
hippuric acid (Rf 0.21), which are possible fission products containing the 14C-
labelled ,f carbon atom of 4-aminostilbene. Hippuric acid (Rf 0 05 in solvent b)
migrated with metabolite M3 on TLCs but was clearly distinguishable from it
by spray reactions.
Faecal metabolites.-Metabolites excreted in faeces were preferentially water
soluble, 75% ofthe radioactivity being recoverable by aqueous extraction. Most
ofthis represented free compounds since 60% ofthe radioactivity was extractable
into ether. Only small amounts of radioactivity were rendered ether soluble
following treatment ofthe aqueous residue with ,-glucuronidase (2%) and sulpha-
tase (5%) and 30% ofthe aqueous radioactivity was associated with water soluble
metabolites.
4'-Hydroxy-AS (Rf 0-20-0-24 in solvent b) was identified on TLC as the major
metabolite in the ether extracts accounting for 55% of the faecal radioactivity.
Trace amounts only ofother metabolites were detected. These were AAS and the
deacetylated compound, 4'-hydroxy-AAS, N-hydroxy-AAS and an unidentified
hydroxylated metabolite with chromatographic properties on TLC similar to those
ofthe urinary metabolite M3.
Metabolism of N-hydroxy-4-acetamidostilbene
Urinary metabolites.-Urinary metabolites of N-hydroxy-AAS were excreted
mainly in a conjugated form, the major fraction being present as sulphuric acid
conjugates (Table IV). Smaller amounts were conjugated with glucosiduronic
TABLE IV.-Classiftcation of Urinary Metabolites of
N-Hydroxy-4-acetamidostilbene,f 14C
Percentage of urinary radioactivity
Sulphuric acid conjugates
Free Ethereal Acid hydrolysed Total
Method of analysis compounds Glucosiduronates sulphates fractions recovery
22*2 14*6 20*8 22*9 80 5
Sequential hydrolysis . 20.6 15 6 19-1 24-4 79.7
Alumina column 25 7 11.9 57 2 94-8
chromatography . 284 12*8 52*4 93-6
acid, together with metabolites present in a free form, the overall excretion
pattern being similar to that observed with the parent amide (Table II).
The nature and quantities of individual metabolites identified both as free
compounds and as sulphuric and glucosiduronic acid conjugates are summarized
in Table V. 4'-Hydroxy-AAS and the deacetylated derivative were the major
metabolites conjugated with sulphuric acid, accounting for 8.9% of the total
urinary radioactivity. Smaller amounts of unchanged N-hydroxy-AAS (0.9%)
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TABLE V.-Urinary Metabolite8 of N-Hydroxy-4-acetamidostilbene
Percentage of urinary radioactivity
Compound Free compounds Glucosiduronates Sulphates
Hydroxylated
metabolites
N-Hydroxy-AAS . 15 3- 9 09
3-Hydroxy-AAS . 2 6 2*0 1 4
4'-Hydroxy-AAS . 14 1 6 3*3
4'-Hydroxy-AS . O3 0 6 5- 6
M3 (RfO*04-0*08) . 100 2-2 2-4
Non-hydroxylated
metabolites
AAS . . . 0-8 0 7 1-3
AS . . 01 0.1 041
M4 (Rf 0.04-008) - 01
and 3-hydroxy-AAS (1-4%) were detected together with an unidentified metabolite
(2.4%) with chromatographic properties (Rf 0u04-008 in solvent b) similar to
those of metabolite M3 of AAS (Table III). This metabolite was also detected
as the free compound (10.0%) and as a glucosiduronate (2.2%) and was the major
metabolite of N-hydroxy-AAS.
3-Hydroxy-AAS, 4'-hydroxy-AAS and the deacetylated compound were
detected as glucosiduronates, but N-hydroxy-AAS was the major metabolite
in this fraction, accounting for 3.9% ofthe urinary radioactivity. Small amounts
of the ring hydroxylated metabolites were also detected as free compounds
together with a small amount of unchanged N-hydroxy-AAS. AAS and the
deacetylated compoundwere identified in each fraction but the amounts were small
compared with hydroxylated metabolites.
DISCUSSION
These investigations show that 4-acetamidostilbene and its N-hydroxy
derivative, like many other aromatic amides, are rapidly eliminated both in
urine and faeces so that only small amounts of the carcinogens remain in the
body four or five days after a single intraperitoneal administration. Such
observations may explain why repeated oral or intraperitoneal dosing with
4-aminostilbene compounds is necessary to elicit a significant carcinogenic response
(Baldwin et al., 1968; Druckrey, Schmahl and Dischler, 1963).
Radioactivity was excreted in comparable amounts in both urine and faeces
following intraperitoneal injection of 14C-AAS into normal rats suggesting the bile
as a significant vehicle for elimination of metabolites. There was, furthermore,
a more marked use of the faecal pathway for the excretion of AAS metabolites
in rats pre-treated with AAS or more particularly N-hydroxy-AAS (Table I).
That these compounds produce marked liver damage has already been reported
(Baldwin et al., 1968) and this is further emphasized by the immediate toxic
effects following a single intraperitoneal injection ofAAS as reflected by morpho-
logical damage to liver mitochondria (Bitensky, Baldwin and Chayen, 1960a
andb). Consequently theincreaseduse ofthefaecalpathwayforexcretionofmeta-
bolites may reflect liver damage perhaps through interference with metabolic
processes such as those concerned with acetylation-deacetylation reactions which
are thought to influence the use of the faecal excretion route (Weisburger,
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Grantham and Weisburger, 1964a). The extensive use of the faecal pathway
for the elimination of AAS metabolites, particularly in rats pre-treated with AAS
or the N-hydroxy derivative, contrasts with findings with other carcinogenic
amides where metabolites are preferentially excreted in urine, For example, the
amount ofurinary metabolites of 2-acetamidofluorene in the rat is at least twice
that in faeces (Weisburger, Grantham and Weisburger, 1964b) and continuous
oral administration of the carcinogen results in a gradually increasing urinary
excretion of the N-hydroxy metabolite (Miller, Cramer and Miller, 1960).
Similarly 2-benzamidofluorene, which is essentially non-carcinogenic, is mainly
excreted in faeces, whilst the major share of the metabolites of the carcinogenic
N-hydroxy-2-benzamidofluorene is found in urine (Gutmann, Galitski and Foley,
1967). The significance of urinary levels of carcinogen metabolites as reflecting
gross tissue levels has been questioned, however, and it has been argued that the
total excretion of metabolites (urine and bile) should be taken into account
(Irving, Wiseman and Hill, 1967). One important consequence of biliary
excretion ofcarcinogen metabolites is that it may establish enterohepatic cycling
(Smith, 1966) resulting in metabolites passing from liver into bile and then into
gut being absorbed and re-circulated. In this context, low levels of radioactivity
are detectable in blood following intraperitoneal injection of14C-AAS, amounting
toapproximately 0.5% ofthe administered dose and this persists for at least 7 days
(Baldwin and Romeril, unpublished results). The transport of N-hydroxy-2-
acetamidofluorene in rat blood has also been observed by Weisburger, Grantham
and Weisburger (1966).
The relevance of metabolic changes in the gut in relation to aromatic amine
carcinogenesis has already been emphasized (Clayson, 1962; Irving, Wiseman and
Hill, 1967) and significantly, N-hydroxy-AAS induces tumours in the gastro-
intestinal tract (Andersen et al., 1964; Baldwin et al., 1968). The re-circulation
ofcarcinogen metabolites excreted into bile may be ofgreater importance, however,
inrelationto thehighcarcinogenic response evoked by N-hydroxy-AAS in ear duct
glands, since aspointed outby Smith (1966) entero-hepatic cycling of a compound
may result in a more prolonged tissue retention.
Thepresent metabolic studies indicate that the major proportion ofthe urinary
metabolites of AAS andN-hydroxy-AAS as well as the faecal metabolites of AAS
are hydroxylated derivatives, either free or conjugated, consisting mainly of
4'-hydroxy-AAS and the deacetylated 4'-hydroxy-AS with smaller amounts of
3-hydroxy-AS (Tables III and V).
Thesefindings confirm earlier studies ofBaldwin and Smith(1965) and moreover
show the presence of 3-hydroxy-AAS previously only detected by Andersen et al.
(1964). In total, about 5 to 6% of the urinary metabolites of both carcinogens
is present as the N-hydroxy compound, representing in both cases about 2% of
the dose administered. These values closely approximate to those previously
obtained by chemical assay (Baldwin and Smith, 1965).
Of the metabolites identified, N-hydroxy-AAS has a greater carcinogenic
activity than the parent amide (Andersen, et al., 1964; Baldwin et al., 1968)
whilst the ring hydroxylated metabolites, 3-hydroxy-AAS and 4'-hydroxy-AAS
are virtually devoid of activity. These findings accord with the now extensive
data implicating N-hydroxylation as an important metabolic activation with
carcinogenic aromatic amines (Miller and Miller, 1966, 1967). These conclusions,
however, do not take into account the unidentified urinary compound (M3) which
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accounted for 10 to 15% ofthe total urinary metabolites ofAAS and N-hydroxy-
AAS (Tables III and V). The significance ofthis metabolite, which was excreted
mainly in an unconjugated form, cannot be evaluated until it has been chemically
identified or an assessment ofits carcinogenic properties has been obtained.
The major fraction of the N-hydroxy-AAS metabolite excreted in urine from
rats treated with AAS was present as a conjugate with glucosiduronic acid and
the urinary levels of this conjugate were about 50% higher in rats treated with
N-hydroxy-AAS. The non-carcinogenic metabolites 4'-hydroxy-AAS and the
deacetylated compounds (4'-hydroxy-AS), which comprise the majorring hydroxy-
lated metabolites, were preferentially excreted as sulphuric acid conjugates. This
suggests that glucosiduronic acid conjugation may be an important metabolic
change in aminostilbene carcinogenesis, perhaps resulting in stabilization of the
N-hydroxy-AAS together with increased water solubility. Both of these effects
must be important if it is postulated that liver metabolites are involved in the
induction of ear duct tumours. In this context, it has been demonstrated that
the glucosiduronic acid conjugate of N-hydroxy-2-acetamidofluorene (N-GLO-
AAF) is a stable compound and it has been isolated and characterized (Irving,
1965). Furthermore, N-GLO-AAF has been shown to undergo interactions
in vitro with methionine, tryptophan and guanosine to yield products the same
as those formed by esters of N-hydroxy-AAF such as N-acetoxy-AAF and
N-benzoyl-AAF (Miller et al., 1968). These interactions were not thought to
depend upon degradation of N-GLO-AAF conjugate, and N-hydroxy-AAF itself
did not react to the same extent. From these considerations it was postulated
that reaction of the glucosiduronic acid conjugate with tissue constituents could
be important in N-hydroxy-AAF carcinogenesis. On this basis, the low response
in liver to aminostilbene carcinogenesis may reflect the efficiency of metabolic
elimination ofthe N-hydroxy metabolite. Conversely, the sensitivity of ear duct
glands may depend upon a low metabolic degradation of carcinogen metabolites
which for reasons not yet understood, become localised in these glands. This is
supported by the observed persistance ofradioactivity in ear duct glands following
intraperitoneal injection of 14C-N-hydroxy-AAS (Baldwin and Romeril, as yet
unpublished). The extent of localization in ear duct glands may be further
enhanced during chronic feeding tests since these glands are altered with increasing
age and it has been suggested (Schardein and Kaump, 1966; Tawfic, 1965) that
cystic dilation in the glands contributes to carcinogenesis.
SUMMARY
4-Acetamidostilbene (AAS) and the N-hydroxy derivative were rapidly
excreted in faeces and urine following intraperitoneal administration to rats.
The use of the faecal metabolic pathway was increased in rats pretreated with
4-aminostilbene compounds.
The major urinary metabolites of AAS identified were 4'-hydroxy-AAS, and
its deacetylated derivative, 3-hydroxy-AAS and N-hydroxy-AAS; the latter being
the only carcinogenic compound. Additionally, a further unidentified metabolite
was detected accounting for 10 to 15% of the urinary metabolites. Faecal
metabolites ofAAS were present mostly as free compounds, the major metabolite
being 4'-hydroxy-AAS.
The N-hydroxy-AAS metabolite excreted in urine from rats treated with AAS
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was mainly conjugated with glucosiduronic acid. The non-carcinogenic meta-
bolites 4'-hydroxy-AAS and the deacetylated compound, 4'-hydroxy-AS, were
preferentially excreted as sulphuric acid conjugates.
The overall metabolism of N-hydroxy-AAS was similar to that of the parent
amide, both with respect to the nature of the urinary metabolites and their
relative concentrations. The major fraction ofN-hydroxy-AAS was excreted as a
glucosiduronic acid conjugate and the urinary levels of this conjugate were about
50%0 higher than in AAS-treated rats.
These observations implicate N-hydroxylation as a metabolic activation
process and it is postulated that the low response of liver to aminostilbene
carcinogenesis reflects the efficiency of metabolic elimination from liver of the
N-hydroxy metabolite in a stable conjugated form. This formation of a stable
conjugate of the N-hydroxy metabolite coupled with the extensive use of the
biliary metabolic pathway should allow wide tissue distribution of the carcinogen
but other factors as yet undefined must also contribute to the high susceptibility
of ear duct glands.
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